Recruiting

The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer

This study investigates plasma metabolites to clarify the relationship between these metabolites and breast cancer, aiming to identify valuable biomarkers. Furthermore, by incorporating clinical information-such as cancer stage, type, treatment outcomes, and prognosis-into prospective studies, the research seeks to further examine the correlation between plasma metabolites, treatment efficacy, and prognosis.

ClinicalTrials.gov IDNCT06698679

PhaseNot Applicable

Enrollment1000

SponsorShengjing Hospital

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

Interventions

Other: No intervention — There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.

Primary outcomes

Cohort 1 : Different Plasma Metabolites (2 years)
Cohort 2: Different Plasma Metabolites (2 years)
Cohort 3: Different Plasma Metabolites (7 years)

Eligibility information

Inclusion Criteria: * Cohort 1 Control Group: women without breast cancer or other malignancies. Case Group: patients with histologically confirmed carcinoma in situ or invasive breast cancer; no prior treatment; no distant metastasis; and not associated with other malignant tumor diseases. * Cohort 2 Pathologically diagnosed as breast cancer; Treatment niave patients; To receive standard neoadjuvant therapy; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1) . * Cohort 3 Patients who have been discharged after breast cancer treatment. Exclusion Criteria: * Histologically undiagnosed breast cancer. Breast cancer with distant metastases. Combined with other malignant tumors. Participants must not have participated in other clinical trials within the past month, unless those trials are observational or non-interventional in nature.

Study locations

Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.